E-LIB Suche - Ergebnisse für: Hillson, Jan L.

1

Alpn-101 (ICOSL vIgD-Fc), a Dual Antagonist of the ICOS and..:

Ramakrishnan, Aravind ; Woolfrey, Ann ; Hillson, Jan...
Transplantation and Cellular Therapy. 27 (2021) 3 - p. S265-S266 , 2021

Link: https://doi.org/10.1016/..

2

First‐in‐human study of the safety, tolerability, pharmacok..:

Yang, Jing ; Lickliter, Jason D. ; Hillson, Jan L....
Clinical and Translational Science. 14 (2021) 4 - p. 1314-1326 , 2021

Link: https://doi.org/10.1111/..

3

Evaluation of the Safety and Efficacy of Avacopan, a C5a Re..:

Merkel, Peter A ; Jayne, David R ; Wang, Chao..
JMIR Research Protocols. 9 (2020) 4 - p. e16664 , 2020

Link: https://doi.org/10.2196/..

4

Molecular profiling of rheumatoid arthritis patients reveal..:

Farutin, Victor ; Prod'homme, Thomas ; McConnell, Kevin...
Arthritis Research & Therapy. 21 (2019) 1 - p. , 2019

Link: https://doi.org/10.1186/..

5

326. A RANDOMIZED PHASE 3 TRIAL EVALUATING THE SAFETY AND E..:

Merkel, Peter ; Jayne, David ; Harigai, Masayoshi...
Rheumatology. 58 (2019) Supplement_2 - p. , 2019

Link: https://doi.org/10.1093/..

6

Pharmacokinetic equivalence, comparable safety, and immunog..:

Hillson, Jan ; Mant, Tim ; Rosano, Molly...
Pharmacology Research & Perspectives. 6 (2018) 1 - p. , 2018

Link: https://doi.org/10.1002/..

7

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokine..:

Ling, Leona E. ; Hillson, Jan L. ; Tiessen, Renger G....
Clinical Pharmacology & Therapeutics. 105 (2018) 4 - p. 1031-1039 , 2018

Link: https://doi.org/10.1002/..

8

TO041CCR2 ANTAGONISM REDUCES PROTEINURIA AND GLOMERULAR INJ..:

Miao, Zhenhua ; Ertl, Linda ; Newland, Dale...
Nephrology Dialysis Transplantation. 32 (2017) suppl_3 - p. iii97-iii97 , 2017

Link: https://doi.org/10.1093/..

9

Derivation of Phase 3 dosing for peginterferon lambda-1a in..:

Wang, Xiaodong ; Hruska, Matthew ; Chan, Phyllis...
The Journal of Clinical Pharmacology. 55 (2014) 1 - p. 63-72 , 2014

Link: https://doi.org/10.1002/..

10

A randomized phase 2b study of peginterferon lambda-1a for ..:

Muir, Andrew J. ; Arora, Sanjeev ; Everson, Gregory...
Journal of Hepatology. 61 (2014) 6 - p. 1238-1246 , 2014

Link: https://doi.org/10.1016/..

11

Derivation of Phase 3 dosing for peginterferon lambda-1a in..:

Hruska, Matthew ; Wang, Xiaodong ; Chan, Phyllis...
The Journal of Clinical Pharmacology. 55 (2014) 1 - p. 73-80 , 2014

Link: https://doi.org/10.1002/..

12

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twel..:

Furie, Richard ; Nicholls, Kathy ; Cheng, Tien‐Tsai...
Arthritis & Rheumatology. 66 (2014) 2 - p. 379-389 , 2014

Link: https://doi.org/10.1002/..

13

Comparison of Alternative Primary Outcome Measures for Use ..:

Wofsy, David ; Hillson, Jan L. ; Diamond, Betty
Arthritis & Rheumatism. 65 (2013) 6 - p. 1586-1591 , 2013

Link: https://doi.org/10.1002/..

14

Atacicept in combination with MMF and corticosteroids in lu..:

Ginzler, Ellen M ; Wax, Stephen ; Rajeswaran, Anand...
Arthritis Research & Therapy. 14 (2012) 1 - p. R33 , 2012

Link: https://doi.org/10.1186/..

15

Abatacept for lupus nephritis: Alternative definitions of c..:

Wofsy, David ; Hillson, Jan L. ; Diamond, Betty
Arthritis & Rheumatism. 64 (2012) 11 - p. 3660-3665 , 2012

Link: https://doi.org/10.1002/..